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Abstract 
ABSTRACT 
Maspin (mammary §.erine 12rotease inhibitor) is a tumour suppressing member of the 
serpin superfamily. Maspin is expressed in normal breast and prostate cells, but 
reportedly down regulated during progression of cancer in these tissues. Maspin has 
been shown to inhibit cellular migration and invasion in vitro ; while in vivo, maspin has 
been shown to inhibit tumour growth, metastasis, and angiogenesis. Maspin also plays a 
role in the sensitisation of cells to induced apoptosis. These functions of maspin are 
independent of serine protease inhibition; however the cellular mobility function is 
dependent on an intact reactive site loop. Despite this knowledge, the molecular 
mechanisms for all reported functions of maspin are currently unknown. 
Mas pin is reported to be transcriptionally regulated; to date Ets, Apl, and p53 
transc1iption factors have been shown to activate transcription of maspin by binding 
directly to the promoter. Androgen is reported to be a negative regulator through the 
binding of the androgen receptor to a hormone response element within the promoter. 
This hormone response element is also responsible for an increase in maspin expression 
in response to tamoxifen, an anti-oestrogen drug. Transcriptional regulation of maspin 
has also been reported to be activated by other molecules, including gamma linolenic 
acid, manganese containing super-oxide dismutase, and nitric oxide, the mechanisms of 
regulation by these molecules is unknown. Loss of maspin expression in cancerous cells 
lines has been attributed to loss of one or more of the activating factors, and aberrant 
methylation of cytosine residues resulting in chromatin compaction. 
This study investigated the transcriptional regulation of maspin, with the aim of 
identifying transcriptional effectors important to the regulation of the gene. 
Identification of such factors may help identify a pathway in which maspin exerts its 
tumour suppressor functions . To this end, the maspin promoter was cloned and 
functional assays carried out, identifying several putative regions of the maspin 
promoter which may be important for the regulation of the gene. To date, the precise 
activator/repressor binding sites and the cognate proteins responsible for this regulation 
are unidentified. 
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Chapter 1 
CHAPTER 1 - Introduction 
1.1 Cancer 
Cells normally have a finite lifespan, and progress through development and 
differentiation to senescence in a regulated and defined manner. Cancer represents the 
situation where cells have lost this regulation and tend to proliferate in an uncontrolled 
manner. Cancer can be caused by multiple genetic and epigenetic changes, resulting in 
decreased expression or inactivation of tumour suppressor genes, and the increased 
expression or activation of oncogenes. The transformation from benign to malignant 
tumour is an important step in cancer progression. This step involves the gain of an 
invasive phenotype, i.e. the ability to invade neighbouring tissues . Malignant tumours 
can then become metastatic, characterised by the spreading of cancerous cells through 
the lymphatic or vascular system to other organs and tissues. Growth of tumours at 
distant sites follows, ultimately resulting in organ failure and death (De Vita et al., 
2001). 
In New Zealand, prostate cancer was the most common form of cancer diagnosed in 
1999 at 98.2 diagnoses per 100,000 people per year, breast cancer followed with 87 .6 
diagnoses per 100,000 people per year. Breast and prostate cancer had the second and 
fourth highest mortality rates respectively in 1999 (NZHIS, 2002). Research world-wide 
is aimed at understanding the mechanisms of cancer development and progression, with 
the ultimate goal being the cure and prevention of cancer. 
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1.2 Maspin 
1.2.1 Expression of maspin 
Maspin (mammary ~erine Qrotease inhibitor) was initially discovered by subtractive 
hybridisation between normal and cancerous breast cell lines, with maspin being 
expressed in normal breast cell lines, whilst down-regulated in breast cancer cell lines 
(Zou et al. , 1994). Expression ofmaspin has since been found in cells of epithelial 
origin; in the mouth, airway, skin, breast, and prostate and also in testis, thymus, and 
small intestine (Zhang et al. , 1997a; Futscher et al. , 2002). In addition, expression of 
mas pin has been reported to be progressively down-regulated as cancers of the breast 
and prostate progress (Zou et al. , 1994; Hojo et al. , 2001 ; Maass et al. , 2001a; Maass et 
al. , 2001c) . Supporting this, the normal breast cell line MCF12a expresses maspin, 
whilst cancerous breast cell lines MDA-MB-231 , MCF7 and T47D do not (figure 1. 1) 
Interestingly, the prostate cancer cell lines PC3 and CA-HPV-10 both express maspin, 
as does the cervical cancer cell line HeLa (see figure 1.1). Hepatocyte carcinoma 
HepG2, lymphoblast K562, and colon cancer CaCO-2 cell lines do not express maspin 
(Bradbury, 2004). 
Figure 1. I . Maspin expression in human cell lines. Cells were grown to - 80% confluence and whole 
cell protein extracted. Protein extracts were then subjected to electrophoresis on an acrylamide gel in 
presence ofSDS. Proteins were then transferred to nylon membrane and probed for maspin and tubulin 
expression. 1 = MCF12a, 2 = MCF7, 3 = MDA-MB-231 , 4 = T-47D, 5 = CA-HPV-10, 6 = PC-3, 
7 = HepG2, 8 = K562, 9 = CaCO-2, 10 = HeLa. Western blot courtesy of Dr Penny Bradbury 
(Bradbury, 2004) 
Tubulin 
Maspin 
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1.2.2 Maspin as a tumour suppressor 
Maspin has been reported to be a tumour suppressor gene, whose function is to inhibit 
cellular mobility, angiogenesis, and increase stress-induced apoptosis in vitro and in 
vivo (Zou et al. , 1994; Pemberton et al., 1995; Sheng et al. , 1996; Sternlicht et al., 1997; 
Seftor et al., 1998; Zhang et al. , 1999; Zhang et al. , 2000b; Zou et al. , 2000; Jiang et al. , 
2002; Shi et al. , 2002). Inhibition of cellular mobility can be affected by the addition of 
recombinant maspin to cultured cells, while apoptosis requires endogenously expressed 
maspin (Sheng et al. , 1994; Zou et al. , 1994; Sheng et al., 1996; Jiang et al. , 2002). 
Myoepithelial cells of the breast are considered to be a protective cell layer (Sternlicht 
et al. , 1997; Reis-Filho et al. , 2002). These cells surround the ductal cell layer (figure 
1.2) and secrete high levels of many serpins, including mas pin, which may act as 
paracrine inhibitors of tumour growth (Sternlicht et al. , 1997). 
Duct 
__ Myoepithelial 
cells 
Surrounding 
tissue 
Figure 1.2. Myoepithelial cells of the breast express maspin. The myoepithelial cell layer expresses high 
levels ofmaspin as shown by brown staining with anti-maspin antibody. The myoepithelial cell layer 
separates the ducts of the breast from the surrounding tissue. Figure courtesy of Dr Penny Bradbury 
(Bradbury, 2004 ). 
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Maspin is mainly present in the cytosol, but also contains an N-terminal signal sequence 
which causes a small amount to be packaged into microsomes and secreted, where it 
acts to inhibit migration and invasion (Zou et al., 1994; Sheng et al., 1996; Pemberton et 
al., 1997; Stemlicht et al., 1997). Although controversial, nuclear localisation of maspin 
has also been demonstrated using imrnunohistochemistry and sub-cellular fractionation. 
Interestingly some tumour cells showed only nuclear localisation of maspin (Maass et 
al., 2002b; Odero-Marah et al., 2002; Reis-Filho et al., 2002; Sood et al., 2002; 
Khalkhali-Ellis and Hendrix, 2003; Kim et al., 2003; Mohsin et al., 2003; Khalkhali-
Ellis et al., 2004). To date, the function of nuclear maspin is unknown. 
Mouse and rat homologues of human maspin have been isolated, and at the amino acid 
level show 89% and 88% identity respectively to human maspin (Umekita et al., 1997; 
Zhang et al., 1997c). Mouse, rat, and human maspin also show similar expression 
patterns and are down-regulated in cancerous cells (Umekita et al., 1997; Zhang et al., 
1997c). Mouse maspin (mMaspin) was shown to exhibit similar characteristics as 
human maspin: reactive site loop-dependent inhibition of cellular migration and 
invasion in vitro (discussed in 1.3.2) (Zhang et al., 1997c). Rat maspin, however did not 
show tumour suppressive properties in vivo (Umekita et al., 1997). 
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1.3 Function of maspin 
1.3.1 Protease inhibition by maspin 
As suggested by its name, maspin shares a high level of identity to the serine protease 
inhibitor (serpin) super-family (Hopkins and Whisstock, 1994; Zou et al., 1994). 
Serpins act by presenting the highly conserved reactive site loop (RSL) to the target 
protease, which recognises and cleaves the RSL. This cleavage results in the protease 
and serpin becoming trapped in a 1: 1 heat and detergent resistant, covalently bound 
complex (Bass et al., 2002). The P1 residue of the RSL determines specificity of the 
serpin for the type of serine protease. Maspin contains an arginine at this residue 
indicating that it is an inhibitor of trypsin-like proteases (Zou et al., 1994). 
It has been suggested that maspin is not an inhibitory serpin i.e. does not inhibit serine 
proteases, as the hinge region of the RSL is highly divergent from known inhibitory 
serpins. The RSL also contains a deletion, leaving maspin with the shortest RSL of all 
serpins (Hopkins and Whisstock, 1994; Pemberton et al., 1995; Fitzpatrick et al., 1996; 
Bass et al., 2002). Maspin was shown to be unable to go through the stressed to relaxed 
transition, which is characteristic of inhibitory serpins, also indicating that maspin is a 
non-inhibitory serpin (Pemberton et al., 1995). Finally, maspin does not inhibit a range 
of trypsin-like proteases, in fact maspin acts as a substrate for these proteases 
(Pemberton et al., 1995; Bass et al., 2002). 
Despite the weight of evidence that maspin is a non-inhibitory serpin, controversy still 
remains. Maspin was demonstrated to inhibit urokinase-plasrninogen activator (uPA) 
and tissue-type plasminogen activator (tPA). uP A and tPA convert plasminogen into 
active plasmin, which in tum degrades the extracellular matrix (ECM) (figure 1.3). Thus 
uPA and tPA cause an increase in cellular mobility (Sheng et al., 1998; Biliran and 
Sheng, 2001). Interestingly, maspin activated the activity of tPA when a co-factor 
(fibrinogen or poly-lysine) was not bound however, maspin acted as a competitive 
inhibitor when a co-factor was bound to tPA (Sheng et al., 1998). 
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Figure 1.3. Schematic representation ofplasmin activation pathway. Plasminogen is cleaved into 
active plasmin by uPA and tPA, which are inhibited by the serpin PAI-1. Active plasmin causes the 
degradation of the extracellular matrix, and thus an increase in cellular mobility. 
uPA was also shown to be inhibited only when associated with the cell surface. The 
levels ofuPA and uPA Receptor (uPAR) were shown to be decreased in cells 
expressing maspin. The authors suggested that this decrease was due to increased 
endocytosis and degradation of a maspin-uPA-uPAR complex (Sheng et al. , 1998; 
Biliran and Sheng, 2001). The inhibition of uPA and tPA dependent proteolysis of 
plasminogen by mas pin may decrease the amount of active plasmin, thus resulting in a 
decrease in ECM degradation and cellular migration (Sheng et al. , 1998; Biliran and 
Sheng, 2001). uPAR is also known to modify the integrin profile of a cell, which may 
also play a role in inhibition of cellular mobility (discussed in 1.3.2) (Biliran and Sheng, 
2001). 
The inhibition of uP A and tP A, and the decrease in uPA and uP AR may explain how 
maspin inhibits cellular migration and invasion, however several publications dispute 
these findings (Zhang et al. , 1999; Bass et al. , 2002). Bass, et al. , (2002) demonstrated 
that maspin does not inhibit cellular mobility by inhibiting proteolysis, and that maspin 
is a non-inhibitory serpin. Under a wide range of conditions, in which plasminogen 
activator inhibitor-I (P AI-1) (figure 1.3), a serpin with a high level of identity to 
maspin, is an effective inhibitor, maspin showed no detectable inhibition of proteolysis 
(Bass et al., 2002). PAI-1 inhibits both cell-surface bound and free uPA with similar 
kinetics, indicating that the cell-surface is not required for the inhibitory activity of this 
serpin. Maspin then, would also be expected to show little difference between bound 
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and non-bound inhibition (Bass et al., 2002). Also, the competitive inhibition shown by 
Sheng, et al., (1998) is not a recognised mechanism of serpin action (Bass et al., 2002) 
Taken together the data indicate that maspin is not an inhibitory serpin, and that the 
inhibition of migration and invasion is not dependent on protease inhibitory activity. 
1.3.2 Cellular mobility 
For a cell to gain the ability to invade, it must modify cell-cell and cell-ECM adhesions 
(De Vita et al., 2001). Proteolysis of the ECM and basement membrane is important for 
the invasion of tumour cells into surrounding tissues. This is carried out by many 
different proteases including metalloproteases and serine proteases (Seftor et al., 1998; 
De Vita et al., 2001; Liotta and Kohn, 2001). Modification of the integrin profile of a 
cell, which mediates the interactions with the ECM, changes the ability of the cell to 
interact with and perceive its environment; thus affecting signal transduction, and can 
lead to the acquisition of an invasive phenotype (Seftor et al. , 1998; De Vita et al., 
2001). 
Maspin has been shown to inhibit the migration of cancerous cells across a membrane, 
and invasion through a membrane in vitro (Sheng et al., 1994; Zou et al., 1994; Sheng et 
al., 1996). Both endogenously expressed, and purified recombinant maspin have been 
shown to inhibit cellular mobility. Maspin exerts this effect at the plasma membrane, 
and cellular mobility can be restored to normal levels by addition of maspin monoclonal 
antibody (Sheng et al., 1994; Zou et al., 1994; Sheng et al., 1996). An antibody to the 
RSL of maspin prevents maspins inhibition of migration and invasion only when pre-
incubated with, or added to the migration assay concurrently with recombinant maspin. 
This indicates that the maspin RSL is buried, and necessary for migration inhibition 
(Sheng et al., 1996). Cleavage at the P1 position of the maspin RSL (thereby removing 
RSL) abrogates the migration inhibitory activity of maspin (Sheng et al., 1994; 
Pemberton et al., 1995; Sheng et al., 1996; Zhang et al., 2000b). Thus the RSL is 
necessary for inhibition of cellular mobility. 
Myoepithelial cell lines have been shown to inhibit invasion and migration of cancerous 
cells. Myoepithelial cell conditioned media (CM) or co-culture has been shown to 
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reduce invasion and migration of cancerous cell lines in vitro. Irnmunoprecipitation of 
maspin from CM abrogates cancer cell mobility inhibition (Sternlicht et al., 1997; Shao 
et al., 2000). This suggests that myoepithelial cells secrete maspin, which inhibits the 
invasion of cancerous cells in a paracrine manner. 
Inhibition of cellular migration and invasion has also been shown in vivo (Zou et al., 
1994; Zhang et al., 1999; Zhang et al., 2000a; Zhang et al., 2000b; Shi et al., 2002). 
Maspin expressing cancerous cells implanted into nude mice, showed reduced tumour 
growth, and number of metastatic sites. This effect was also seen if maspin was 
delivered as a recombinant protein, or as an expression vector in liposome mediated 
gene therapy (Zou et al. , 1994; Zhang et al., 2000b; Shi et al., 2002). 
Transgenic mice containing maspin under the influence of the whey acidic protein 
(W AP) promoter, which is expressed exclusively in mammary epithelial cells during 
mid-pregnancy and lactation, showed disrupted mammary gland development (Zhang et 
al., 1999). This was due to the inability of the cells to migrate, and increased apoptosis 
(Zhang et al., 1999). Mice containing the SV-40 T-antigen under the control of the 
WAP promoter (WAP-TAg) produce mammary tumours with 100% efficiency. These 
mice were crossed with WAP-maspin mice (Zhang et al., 2000a). When compared to 
WAP-TAg mice, WAP-TAg:WAP-maspin bi-transgenic mice showed a reduction in 
tumour growth, and number of lung metastases, however maspin did not affect tumour 
initiation (Zhang et al. , 2000a). Thus endogenously expressed maspin inhibits tumour 
growth and migration to metastatic sites in vivo. 
Addition of recombinant maspin to non-expressing cancerous cells has been shown to 
change the integrin profile of these cells (Seftor et al., 1998). Cells expressing maspin 
had increased levels of a3 and as containing integrins, whilst decreased levels of other 
integrin monomers was observed. This addition of maspin inhibited cellular migration, 
which was reversed by the addition of as~1 integrin antibody (Seftor et al., 1998). 
Maspin has also been demonstrated to interact with collagen type I and III (Blacque and 
Worrall, 2002). Binding to collagen was within a region of the maspin protein which 
shares homology to the collagen binding protein colligin, and was independent of the 
RSL (Blacque and Worrall, 2002). These reports may help explain how maspin inhibits 
cellular migration and invasion; however the mechanism of action is unknown. 
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Taken together these data suggest that maspin can inhibit cellular migration and 
invasion in vitro and in vivo; and can act in an autocrine and paracrine manner. The 
molecular mechanisms responsible for the inhibition of cellular mobility are as yet 
unknown; however they may involve binding to collagen and/or modification of the 
cellular integrin profile. Inhibition of cellular mobility by maspin is dependent on an 
intact RSL, however does not involve inhibition of serine proteases (discussed in 1.3.1). 
1.3.3 Role of maspin in apoptosis 
Cells expressing maspin have been shown to be more sensitive to stress-induced 
apoptosis (Jiang et al., 2002; Khalkhali-Ellis and Hendrix, 2003). In breast cancer cells, 
increased levels of nitric oxide (NO) induced maspin expression and an increase in 
apoptosis. This increase in apoptosis was partially reduced by the addition of maspin 
antibody (Khalkhali-Ellis and Hendrix, 2003). NO pro-apoptotic effects are believed to 
be due to an increase in p53, activation of the caspase cascade, and DNA fragmentation 
(Khalkhali-Ellis and Hendrix, 2003). Supporting these suggestions Jiang, et al., (2002) 
demonstrated that maspin expressing cells were more sensitive to staurosporine (STS)-
induced apoptosis, due to increased caspase activation. (Jiang et al., 2002). Protein 
kinase C prevents caspase-dependent apoptosis, STS induces apoptosis by inhibition of 
this enzyme. Maspin was shown to increase levels of caspase 3 and caspase 8 activity 
upon STS treatment; this was associated with increased DNA fragmentation and 
apoptosis. Increased apoptosis was not seen in untreated maspin expressing cells, 
indicating that maspin did not increase apoptosis directly, but sensitised cells to 
apoptotic inducers (Jiang et al., 2002). 
PAI-1, a close relative of maspin, is an inhibitory serpin which inhibits the plasminogen 
activator-dependent proteolysis of plasminogen into active plasmin. This activation of 
plasmin results in the increased degradation of the ECM. Thus PAI-1 is an inhibitory 
serpin which inhibits cellular migration and invasion. Recombinant maspin, conditioned 
media, and N- and C-terminal maspin:PAI-1 fusion proteins did not sensitise cells to 
induced apoptosis, indicating that this is a function of intracellular maspin, and 
dependent on an intact protein (Jiang et al., 2002). Both N- and C-terminal maspin:PAI-
1 fusion proteins inhibited cellular mobility, indicating that the fusion proteins were 
correctly folded and functional. 
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An increase in apoptosis in tumour cells when expressing maspin was observed in the 
W AP-TAg!W AP-maspin, bi-transgenic mouse model (see Chapter 1.3.2), when 
compared to the W AP-TAg single transgenic mouse (Zhang et al., 2000a). Also the 
W AP-maspin single transgenic mice were shown to have disrupted mammary gland 
development during pregnancy. This was due to the inappropriate expression of maspin 
causing a decreased rate of migration and increased apoptosis (Zhang et al., 1999). The 
cause of this increased rate of apoptosis in W AP-maspin mice is unknown, however it 
may be due to inappropriate integrin-ECM contacts/signalling due to inhibition of 
migration (Zhang et al., 1999). Maspin expressing cells may be more sensitive to 
apoptosis caused by such inappropriate integrin interactions. 
Taken together, maspin sensitises cells to stress-induced apoptosis in vitro and in vivo. 
Maspin increases the activation of caspase 3 and 8, resulting in increased DNA 
fragmentation, and cell death. This function seems to be dependent on intact 
intracellular maspin. The molecular mechanism of the sensitisation of cells to induced 
apoptosis is currently unknown. 
1.3.4 Maspin and angiogenesis 
Angiogenesis is the development of new blood vessels from existing capillaries 
(Beecken et al., 2000). Tumour growth is angiogenesis-dependent, as cells in the centre 
of a tumour become hypoxic due to lack of nutrients and oxygen. This hypoxia causes 
proliferation and apoptosis of tumour cells to be in balance (Beecken et al., 2000). 
Metastasis is also angiogenesis-dependent as tumours require access to vessels to be 
able to spread to other organs (Beecken et al., 2000). 
Maspin, independently of the RSL, inhibited the ability of prostate cancer cells to 
migrate toward vascular epithelium growth factor (VEGF), a stimulator of angiogenesis 
in vitro (Zhang et al., 2000b). Prostate cancer cells, grafted into nude mice, were 
supplied with exogenous maspin and the effect on tumour growth and vascularization 
measured. Maspin reduced the size of tumours and the density of vascularization 
compared to controls (Zhang et al., 2000b). In corneal neovascularization experiments, 
pellets containing basic fibroblast growth factor (bFGF), an angiogenesis stimulator, 
and maspin (mutant and normal) were implanted into rat corneas. Maspin, and maspin 
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lacking the RSL inhibited the formation of vessels, whilst maspin lacking the N-
terminus had no effect (Zhang et al., 2000b). Thus as bFGF acts as a paracrine 
angiogenesis stimulator, maspin with an intact N-terminus, independent of the RSL, 
acts as a paracrine angiogenesis inhibitor. This report is supported by WAP-TAg/W AP-
maspin bi-transgenic mice which showed a decrease in tumour vascular density (Zhang 
et al., 2000a). In addition, a clinical study carried out by Rojo, et at., (2001) 
demonstrated that vascularization was significantly inhibited in breast tumours 
expressing maspin. 
These reports indicate that maspin acts as an inhibitor of angiogenesis in vivo. Maspin 
can exert this effect in a paracrine manner, and is independent of the RSL. Blacque and 
Worrall, (2002) showed that maspin could bind collagen I and III independently of the 
RSL. This binding may play a role in the inhibition of angiogenesis; however its 
significance is yet to be demonstrated. 
1.3.5 Phosphorylation of maspin 
Maspin has also been shown to be phosphorylated on tyrosine residues (Odero-Marah et 
al., 2002). Phosphorylation of tyrosine residues can be important for enzyme activity 
and/or signal transduction. Maspin was shown to be phosphorylated in normal and 
cancerous cell lines, and was phosphorylated by the tyrosine kinase domain of the 
epidermal growth factor receptor (Odero-Marah et al., 2002). The potential change of 
function upon phosphorylation of maspin was not studied. The phosphorylation of 
maspin may be involved in activation or inhibition of the protein; or may be part of a 
signal transduction pathway. 
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1.4 Clinical studies 
1.4.1 Prognostic value 
Maspin has been reported to be present in normal breast and prostate tissue but down-
regulated, or lost in cancers of these tissues (Zou et al., 1994; Hojo et al., 2001; Maass 
et al., 2001a; Maass et al., 2001c). This, along with the reported tumour suppressor 
functions of maspin suggest that the loss of maspin may contribute to the progression of 
cancer. Initial studies indicated that major mutations/rearrangements of the maspin gene 
did not contribute to the loss of maspin, indicating that maspin was down-regulated 
rather than mutated (Zou et al. , 1994). Many clinical studies have been carried out 
testing the prognostic value of maspin in several different cancer types. If maspin is not 
mutated, and loss of maspin is important for the progression of cancer, then maspin 
expression in cancers may be a prognostic marker for a less aggressive cancer. 
1.4.2 Breast carcinomas 
Many studies have been carried out on maspin expression in breast cancers. Several 
studies have shown that maspin is down-regulated during breast cancer progression 
(Zou et al., 1994; Maass et al., 2001c). Maass, et al., (2001c) showed a stepwise 
decrease in maspin expression as cancers progressed from ductal carcinoma in situ 
(DCIS) to invasive carcinoma to lymph node metastases; however a subset of invasive 
tumours were shown to express high levels of maspin. Another study by Maass, et al., 
(2001a) indicated that loss of maspin correlated with a higher risk of distant metastasis 
and shorter disease free survival. These results were supported by Hojo, et al., (2001). 
In other reports, maspin expression has been correlated with poor prognosis (Umekita et 
al., 2002; Umekita and Yoshida, 2003). A step wise increase from DCIS to invasive 
cancer was seen (Umekita and Yoshida, 2003). Maspin expression correlated with 
larger tumour size, higher histological grade, and shorter disease free survival, and may 
have been related to an aggressive phenotype (Umekita et al., 2002; Umekita and 
Yoshida, 2003) 
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Mohsin, et al., (2003) studied nuclear and cytoplasmic maspin staining, and breast 
cancer progression; 96% of cancers stained for maspin showed nuclear staining, whilst 
· 35% showed cytoplasmic staining. Nuclear staining was associated with good 
prognosis, and presence of oestrogen and progesterone receptor (ER and PR 
respectively). Cytoplasmic staining was correlated with the absence of ER and PR; and 
poor prognosis (Mohsin et al., 2003). 
Another study showed that maspin was frequently associated with a higher histological 
grade, similar to the subset of invasive tumours found by Maass, et al., (2001c) which 
showed strong maspin staining (Kim et al., 2003). The histological grade of a tumour is 
influenced by the percent of tubular structures; size and shape of cells (uniformity); and 
rate of growth as determined by number of cells undergoing mitosis. Tumours are 
graded from 1 to 3, a tumour with a higher grade is more aggressive, faster growing, 
with poorly differentiated cells (www.imaginis.com). Kim et al., (2003) investigated 
192 specimens, wi~h 13% of tumours stained having high expression of maspin. Nuclear 
and cytoplasmic staining was noted. Maspin staining was not of prognostic value, and 
differed between types of breast cancer (Kim et al., 2003). 
Maspin staining in breast cancers is controversial. Different methods of staining, 
quantification of staining, nuclear and cytoplasmic staining, and statistical analyses may 
be the cause of some of these reported differences. The contradictory nature of these 
results suggests that more large studies need to be carried out to determine if maspin 
expression in breast cancers is of any prognostic value. 
1.4.3 Prostate carcinomas 
Several clinical studies on prostate cancers (PC) have been carried out. Machtens, et al., 
(2001) showed that a decrease in maspin expression correlated with the loss of cellular 
differentiation, increased tumour grade, and shorter disease free survival. Zou, et al., 
(2002) also showed that a decrease in maspin expression correlates with 
dedifferentiation of the tumour. 
Pierson et al., (2002) demonstrated that prostate epithelial cells express maspin; 
however the secretory cells from which PC arises did not. Interestingly the pre-
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malignant prostate tumours, and surrounding cells, were shown to express maspin 
(Pierson et al., 2002). Thus maspin is up-regulated in the pre-cancerous stage of prostate 
cancer development. The pre-malignant stage can preceed PC by up to 10 years, and 
Pierson, et al., (2002) suggested that this up-regulation of maspin may prolong the pre-
malignant stage, and may act as a marker for potential PC development. This report also 
demonstrated that once past the pre-malignant stage, maspin expression inversely 
correlated with prostate cancer tumour grade, and was down-regulated step-wise as 
cancer progresses (Pierson et al., 2002). 
Maspin expression in prostate cancers is less controversial than in breast cancers, with 
all reports to date indicating that maspin expression correlates with higher grade PC. 
This may be due to fewer reports on maspin expression in prostate cancers. The up-
regulation of maspin in pre-malignant prostate cancers may be a cellular response to 
tumourigenic changes, however whether maspin up-regulation in the pre-malignant to 
PC transition is a direct or indirect cellular response needs further investigation. 
1.4.4 Other carcinomas 
Studies in cancers of other tissues have also been conducted. In oral squamous cell 
carcinomas, maspin expression correlated with higher survival rates, and absence of 
lymph node metastases (Xia et al., 2000). This report also suggested that maspin 
expression may be a favourable prognostic marker in this type of cancer. 
High levels of maspin expression have been shown in most pancreatic cancers, whilst 
normal pancreatic cells do not express maspin (Maass et al., 2001b; Ohike et al., 2003; 
· Sato et al., 2003). In tumour specimens studies by Maass, et al., (2001b), 23 out of 24 
expressed maspin; while 51 out of 57 tumours studied by Ohike et al., (2003) expressed 
maspin. Maspin expression was correlated with low grade (gradel) pancreatic cancers 
(Ohike et al., 2003). Maass, et al., (2001b) showed that maspin expression increased 
with the malignancy grade of the tumour. 
A similar trend in maspin expression was seen in ovarian cancers (Sood et al., 2002). 
Maspin expression was not found in normal ovary tissue, whilst maspin was present in 
71 % of ovarian invasive cancers, and was correlated with a higher tumour grade. 
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Interestingly cancers with greater than 50% nuclear staining were associated with 
improved patient survival (Sood et al., 2002). Three mutations in maspin were reported 
in two ovarian cancerous cell lines. One of these mt-maspin cell lines was transfected 
with wt-maspin, resulting in inhibited cellular migration, which was abrogated by 
addition of maspin antibody (Sood et al., 2002). This suggests that the mt-maspin 
expressed in this cell line is not functional in cellular mobility inhibition. This raises the 
possibility that maspin may be mutated in ovarian cancers. Maspin mutations have also 
been reported in prostate cancer cell lines (Umekita et al., 1997) 
The tumour suppressive function of maspin seems to be supported by its down-
regulation in prostate and oral carcinomas, while the case for maspin down-regulation is 
not so clear cut in breast cancers. Up-regulation of maspin in ovarian and pancreatic 
cancers however, does not support maspin as a tumour suppressor. Pancreatic and 
ovarian cells may not be responsive to maspin i.e. interacting partners may not be 
present in these tissues; however maspin is up-regulated in a large proportion of 
pancreatic and ovarian cancers, which indicates expression of maspin is an advantage to 
these cancers. It is possible that maspin expressed in these cancers is mutated. This 
mutant form may carry out a function facilitating cancer progression. Few maspin 
mutations have been reported to date, and so little is known about the frequency of such 
mutations in cancers and their effect on cancer cells. 
1.5 Regulation of maspin expression 
1.5.1 Regulation of RNA polymerase II genes 
Eukaryotes contain three RNA polymerase enzymes, of which only RNA polymerase II 
transcribes hn-RNA (heterogeneous-nuclear RNA), the precursor to mRNA. RNA 
polymerase II cannot directly recognise the promoter of target genes, and thus requires 
additional factors for the recognition of a promoter and subsequent transcription of the 
gene. Transcription factor II D (TFIID) is essential for transcription of RNA polymerase 
II genes. TFIID is a multi-subunit protein, made up of TATA box-binding protein 
(TBP) and TBP-associated factors (T AFs). TFIID is responsible for the recognition of 
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the TATA box element of a promoter. The TATA box is an important element in many 
promoters which binds TFIID resulting in the positioning of the polymerase over the 
transcription start site and activation of transcription. TFIID recognises and binds to the 
TATA box through the TBP subunit. Other essential factors including TFIIA and TFIIB 
are then recruited by the DNA bound TFIID. RNA polymerase then binds; this 
assembled complex, which is capable of transcriptional activation, is called the basal 
apparatus. The binding of RNA polymerase II to the assembled transcription factor 
complex positions the polymerase, allowing transcription to occur, with additional 
factors binding to help the polymerase clear the promoter. 
Despite the importance of the TAT A box, many promoters do not contain this element; 
such promoters are termed TATA-less promoters. In TATA-less promoters, the TBP 
sub-unit of TFIID cannot directly bind to the DNA. In these cases TFIID (or TFIIB) is 
recruited by transcriptional activators (e.g. Spl) which are bound to the promoter at 
their corresponding element. Protein-protein interactions between activation domains of 
the transcription factor, or co-activator, and TAF sub-units anchor TFIID to the 
promoter, allowing the basal apparatus to assemble, and leading to the transcription of 
the gene. Thus, the transcription of TAT A-less promoters relies upon TFIID sub-unit 
interactions with activating transcription factors (Weaver, 1999). The maspin promoter 
is a TATA-less promoter (Zhang et al., 1997a). 
1.5.2 Transcriptional regulation of maspin 
Maspin is regulated transcriptionally, and is classed as a class II tumour suppressor 
gene, because it is down-regulated rather than mutated (Lee et al., 1991; Zou et al., 
1994 ). Several different factors have been shown to bind to the maspin promoter and 
activate/repress maspin transcription (figure 1.3). All regulatory factor sites reported to 
date are located within 500 base pairs (bp) of the transcription start site (TSS). Ets, Apl 
and p53 sites have been shown to be important for the activation of transcription, whilst 
androgen receptor (AR) binding to the hormone response element (HRE) represses 
transcription (Zhang et al., 1997a; Zhang et al., 1997b; Zou et al., 2000). Methylation of 
CpG di-nucleotides in this region of the promoter has also been shown to inhibit trans-
activation of maspin (Domann et al., 2000; Futscher et al., 2002; Maass et al., 2002a; 
Oshiro et al., 2003; Sato et al., 2003). 
16 
Chapter 1 
+1 
.. p53 • Ets 
I Apl HRE 
Figure 1.3. Reported regulatory elements contained in the maspin promoter. All sites are 
contained within 500 bp of the transcription start site. Thick black line indicates DNA, bent arrow 
indicates TSS (Zhang et al. , 1997a; Zhang et al. , 1997b; Zou et al. , 2000). 
1.5.3 Ets transcription factor 
Two binding sites for the Ets family of transcription factors have been reported within 
500 bp of the TSS (Zhang et al. , 1997a; Zhang et al. , 1997b) (figure 1.3). The proximal 
Ets site was sufficient for transcription of the reporter gene-mas pin promoter construct 
in normal breast and prostate cell lines (Zhang et al. , 1997a; Zhang et al. , 1997b). 
Transient transfections in cancerous breast cell lines showed decreased trans-activation 
by the Ets site. This suggests that the decrease in maspin expression in breast cancer 
cells may be due in part to decreased transactivation by the Ets factors. 
Ets (E26 transformation-specific) is a family of proteins which are known to play a role 
in apoptosis, cell proliferation, and differentiation. About 30 members of the Ets family 
have been identified to date, all containing a highly conserved, approximately 85 amino 
acid, Ets DNA binding domain (Verger and Duterque-Coquillaud, 2002; Oikawa and 
Yamada, 2003). The Ets domain confers specific binding to a sequence containing the 
core GGA(NT) sequence, with the surrounding sequence and binding partners defining 
the specificity of the Ets protein for a particular site (Verger and Duterque-Coquillaud, 
2002; Oikawa and Yamada, 2003). Some Ets proteins are ubiquitously expressed, while 
expression of others is developmentally regulated, or tissue-specific (Oikawa and 
Yamada, 2003). Some Ets transcription factors are targets of the Ras/MAP kinase 
signalling cascade, and have been implicated in breast cancer progression (Feldman et 
al., 2003; Oikawa and Yamada, 2003). 
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Pdef (prostate derived Ets factor) was shown to activate transcription of the maspin 
promoter in HeLa cell line transient transfections (Feldman et al., 2003). Pdef was 
found to be present in prostate, colon and breast tissue, and seemed to be down-
regulated in invasive breast cancer cell lines. Pdef was not present in tissues of non-
epithelial origin. The activation induced by Pdef, was reduced by co-transfection with 
Ets-1 (Feldman et al., 2003). This demonstrates that Ets factors are competing for 
binding sites, and so up-regulation of an Ets factor which does not activate maspin may 
cause a decrease in maspin expression by competing for the Ets binding site. The mouse 
Pdef (mPse) has also been shown to activate expression of the human maspin promoter 
in transient transfections using human kidney 293T cell line (Yamada et al., 2000). This 
indicates Ets factors have conserved recognition sequences, and possibly function . 
1.5.4 Apl 
In breast cell lines, the transcription factor Apl (Activating protein- I) was shown to co-
operate with Ets to activate maspin-reporter expression in transient transfections (Zhang 
et al., 1997a). Apl was not sufficient to activate transcription of the reporter gene, 
however with a functional Ets site a large increase in expression was seen compared to 
the Ets site alone (Zhang et al. , 1997a). 
Apl is a family of proteins that homo or heterodimerise to activate transcription of 
target genes (Shaulian and Karin, 2001). Apl proteins play a role in cell proliferation, 
neoplastic transformation, and apoptosis. Formation of active dimers by differential 
regulation of Apl monomers and phosphorylation of Apl contribute to the regulation of 
target genes (Shaulian and Karin, 2001). Apl proteins, like Ets transcription factors, are 
under control of the Ras/MAP kinase signalling cascade. Apl proteins can also be 
activated by UV, growth hormones, and alkylating agents (Shaulian and Karin, 2001). 
The identification of the Apl dimer which along with Ets is responsible for co-operative 
activation may help identify the stimulus which results in maspin expression. 
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1.5.4 p53 
Another positive regulator of maspin expression, present within 500 bp of TSS, is the 
p53 element (Zou et al., 2000). Elevated levels of maspin expression were seen after 
exposure of cells containing wt-p53, to DNA-damaging agents. This effect was not seen 
in mt-p53 cells (Zou et al., 2000). p53 bound to the maspin promoter in electrophoretic 
mobility shift assays (EMSA), and p53 could not activate transcription when the p53 
site was mutated (Zou et al., 2000). 
Oshiro, et al. , (2003) showed that transfection of MDA-MB-231 breast cancer cell lines 
with wt-p53 increased maspin transcription by modification of histones present at the 
promoter. The maspin promoter in MDA-MB-231 cell lines is reported to be 
methylated, and in a compact chromatin structure (see 'CpG methylation' below) 
(Maass et al., 2002a). Transfection of p53 expression vector did not effect the 
methylation status of the promoter, but allowed transcription by recruiting histone 
acetylases and opening up chromatin structure (Oshiro et al., 2003). 
These studies were supported by a report by Umekita, et al., (2002), which showed that 
maspin expression positively correlated with p53 expression in breast cancer patients. 
Interestingly, a clinical study carried out on prostate cancer patients indicated that 
expression of p53 was correlated with lower maspin expression (Machtens et al., 2001). 
This result may be partially explained by a recent report which showed that missense 
p53 mutants could repress expression of target genes in a dominant negative manner 
(Willis et al., 2004). Missense mutations are the most common type of mutation in p53 
(Gasco et al., 2002), and may cause repression of maspin transcription. This may be 
responsible for the correlation between p53 expression and the absence of maspin in 
prostate cancers. Interestingly only 20% of breast cancers express a mutant p53 allele, 
possibly explaining why p53 correlated with maspin expression in breast cancers 
(Gasco et al., 2002). 
p53 is known to be involved in DNA repair, apoptosis and cell cycle arrest; the 
regulation of maspin by p53 may also indicate that p53 is involved in angiogenesis and 
inhibition of metastasis (Gasco et al., 2002). 
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1.5.S Hormone response element 
The presence of a hormone response element (HRE) in the maspin promoter has also 
been shown (Zhang et al., 1997b). This element was responsive to the androgen 
receptor (AR) in prostate cell lines, and caused transcriptional repression of a reporter 
gene in transient transfections. Interestingly this repression was mediated independently 
of the androgen ligand (Zhang et al., 1997b ). This androgen-independence may be due 
to hormone analogues contained within the media, as charcoal stripped foetal calf serum 
(FCS) and phenol red free media were not used in these experiments. Supporting this, 
maspin-reporter gene expression was increased, in androgen responsive prostate cancer 
cell lines, when cultured in charcoal stripped FCS (Zou et al., 2002). This reporter gene 
expression was reduced upon growth with supplemented androgen. Attempts to 
reproduce the EMSA experiments performed by Zhang, et al., (1997b) showed weak 
non-specific binding of AR to the maspin HRE (van Dijk, 2003; Bradbury, 2004). 
The role of androgen in the regulation of maspin in prostate cancers was supported by 
androgen ablation studies. Patients who underwent androgen ablation treatment before 
surgery showed significantly increased maspin expression (Zou et al., 2002). Prostate 
cancer cells showed greater maspin expression when implanted into castrated mice 
compared to non-castrated (Zou et al., 2002). It has also been shown that anti-androgen 
treatment of breast cancer cell lines (which over-express AR compared to normal breast 
cells) caused an increase in maspin expression (Khalkhali-Ellis et al., 2004). 
Interestingly no difference in prostate, kidney, or intestinal maspin expression was seen 
in normal and castrated rats, indicating rat maspin is not responsive to androgen 
(Umekita et al., 1997). 
Androgen receptor plays a role in the development and differentiation of male sex 
organs, and also plays a role in prostate carcinogenesis (Cato and Peterziel, 1998; 
Bonaccorsi et al., 2000). The unliganded androgen receptor is normally present in the 
cytoplasm and upon binding to the androgen hormone, the receptor-ligand complex is 
translocated to the nucleus where it binds to DNA as a homodimer activating or 
repressing transcription (Cato and Peterziel, 1998). 
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Tamoxifen is an anti-oestrogen drug, used in cancer treatment, which competes with 
oestrogens for the oestrogen receptor (ER) (Khalkhali-Ellis et al., 2004). Treatment of 
breast cancer cell lines expressing ER with tamoxifen decreases invasion and migration, 
and increases apoptosis (Khalkhali-Ellis et al., 2004). Oestrogen, progesterone, and 
dihydrotestosterone had no effect on maspin expression, however treatment with 
tamoxifen increased expression in breast cancer cells, and in myoepithelial cells 
secretion of maspin was increased without increasing mRNA levels (Shao et al., 2000; 
Khalkhali-Ellis et al., 2004). Tamoxifen was shown to activate ER~, but not ERa, and 
mutation of the maspin HRE abrogated the effect of tamoxifen on maspin expression 
(Shao et al., 2000; Khalkhali-Ellis et al., 2004). Increased maspin expression was not 
seen in MCF12a normal breast cells when treated with tamoxifen; however secreted 
maspin was not measured (Bradbury, 2004). 
These data indicate that maspin is repressed by the androgen receptor, in response to 
androgen, in human and mice, but not rats. This suggests that maspin may have a role in 
development of male sex organs in mice and humans. The activation of maspin by anti-
oestrogen suggests that other hormones may also play a role in regulation of maspin. 
1.5.6 Other regulatory molecules 
Maspin has been shown to be activated by several other mechanisms, however as yet 
the mechanism of action of these activators is not known. Manganese containing super-
oxide dismutase (MnSOD) is a protein which converts oxygen radicals, a by-product of 
metabolism, into peroxide which is then converted to water by catalase. Oxygen radicals 
can react with proteins, lipids, and DNA potentially causing cellular and DNA damage 
(Li et al., 1998; Cullen et al., 2003). Super-oxide radicals may promote cellular 
proliferation, differentiation, and apoptosis by changing the redox potential of the cell, 
thus regulating redox-sensitive signal transduction pathways (Li et al., 1998; Cullen et 
al., 2003). 
MnSOD is lost, or down-regulated in many cancer cell lines. Re-expression of MnSOD 
in MCF-7 breast cancer cell line, reduced cellular migration and invasion, concomitant 
with maspin re-expression (Li et al., 1998). Maspin re-expression was MnSOD dose 
dependent (Li et al., 1998). This indicates that maspin is activated by MnSOD, however 
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MnSOD is localised in mitochondria (Cullen et al., 2003), and so maspin induction due 
to MnSOD is likely to be indirect. Thus the re-expression of MnSOD in cancer cells 
may restore redox potential, thus restoring redox-sensitive signalling, increasing maspin 
expression. 
Nitric oxide (NO) has also been shown to activate maspin expression (Shao et al., 2000; 
Khalkhali-Ellis and Hendrix, 2003). Increasing NO in media, or expression of 
endothelial nitric oxide synthase (eNOS) in MCF7 breast cancer cells caused re-
expression of maspin (Khalkhali-Ellis and Hendrix, 2003). Increased levels of maspin 
correlated with decreased migration and invasion, and increased apoptosis (Khalkhali-
Ellis and Hendrix, 2003). 
Interestingly, increased NO levels have been shown to cause p53 phosphorylation and 
acetylation in a DNA damage-like response. This corresponded to increased levels of 
p53 target gene trans-activation (Hofseth et al., 2003). The MCF7 cell line used in the 
above experiments has been shown to express wt-p53 (Vojtesek and Lane, 1993). This 
may indicate NO treatment results in increased maspin expression by increasing p53 
trans-activation; however this remains to be proven. 
Gamma linolenic acid (OLA) has also been shown to induce maspin expression (Jiang 
et al., 1997; Jiang et al., 2000). The action of OLA was shown to be mediated through 
Perixosome proliferator activated receptor y, which was translocated into the nucleus 
upon OLA treatment (Jiang et al., 2000). OLA is believed to be an anti-cancer fatty 
acid, with animals on a pure OLA diet showing a decrease in the occurrence of cancer 
(Jiang et al., 2000), however OLA treatments used by Jiang, et al., (1997 & 2000) in 
cell culture experiments seemed to be outside physiological levels (50 - 75 µM). 
These reports show that other mechanisms can up-regulate the expression of maspin, 
however they seem to be indirect. The exact method of maspin regulation by these 
modulators is yet to be demonstrated. 
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1.5.7 CpG methylation 
Methylation on the cytosine residue of CpG dinucleotides in the promoter region of 
genes has been demonstrated to prevent transcriptional activation of genes (Brown and 
Strathdee, 2002). Addition of a methyl group to the cytosine residue can prevent the 
binding of some transcription factors; however this is not believed to be the main 
mechanism by which methylation prevents trans-activation. Methylation leads to the 
binding of methyl-CpG binding proteins (MeCP), which recruit histone deacetylases, 
therefore causing compaction of chromatin in the methylated area (Brown and 
Strathdee, 2002). This compaction of chromatin prevents transcription factors gaining 
access to their respective binding sites, resulting in loss of trans-activation. 
Methylation of the maspin promoter has been shown to prevent expression of maspin in 
some cancerous cells, and also in cells from non-expressing tissues (Domann et al., 
2000; Futscher et al., 2002; Maass et al., 2002a; Oshiro et al., 2003; Sato et al., 2003). 
The maspin promoter has been reported to contain two CpG islands (Domann et al., 
2000). A CpG island is defined as a region of DNA that has an unusually high cytosine 
(C), guanine (G), and CpG di-nucleotide content (Costello and Vertino, 2002). The 
proximal CpG island of the maspin promoter overlaps the transcription start site and 
positive effector sites reported to date. This island was shown to be highly methylated in 
cancerous cell lines, and tissues which do not normally express maspin, whilst maspin 
expressing cells had little methylation in this region. The distal CpG island is located 
approximately 120 bp upstream of the proximal island and was shown to be methylated 
in both expressing and non-expressing cells (Domann et al., 2000; Futscher et al., 2002; 
Maass et al., 2002a; Oshiro et al., 2003; Sato et al., 2003). 
In cell lines which contained methylation of the proximal island, maspin could be re-
expressed by addition of a histone deacetylase inhibitor, and/or methyltransferase 
inhibitors (Domann et al., 2000; Costello and Vertino, 2002; Maass et al., 2002a; Oshiro 
et al., 2003; Sato et al., 2003). Pancreatic tissue does not express maspin, however many 
pancreatic cancers do. Treatment of normal pancreatic cells with methyltransferase, and 
histone deacetylase inhibitor caused expression of maspin in these cells. Cancerous 
pancreatic cells were hypomethylated, whilst normal cells were found to be 
hypermethyalated (Maass et al., 2001b; Ohike et al., 2003; Sato et al., 2003). p53 was 
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able to induce maspin expression in cells with methylated promoters by recruiting 
histone acetylases, which in turn caused the opening of chromatin structure, thus 
allowing transcription factors to bind (Oshiro et al., 2003). 
These findings indicate that at least some factors required for maspin transcription are 
present in many, if not all, tissues and cancers. This suggests that a major loss of maspin 
transcription may be due to methylation of the promoter, and concomitant histone 
compaction. The loss of trans-activation of maspin in methylated cell lines may be 
controlled by the balance of MeCP induced histone acetylation and p53 induced 
deacetylation. Thus the status and expression levels of p53 may be important. 
1.6 Chapter summary 
Maspin is a tumour suppressor gene whose expression has been observed in many 
tissues of epithelial origin, including prostate and breast. The tumour suppressive 
function of maspin is related to its ability to inhibit cellular mobility and invasion, 
apoptosis, and angiogenesis in vitro and in vivo. Whilst some interaction partners have 
been identified, no mechanism is known for the reported functions of maspin. Although 
maspin is a non-inhibitory serpin, inhibition of cellular migration and invasion is 
dependent on the RSL, however angiogenesis inhibition is reliant upon the N-terminus. 
This indicates that maspin contains at least two functional sites. 
Maspin was initially reported to be down-regulated in breast cancers. Several reports 
support this hypothesis, however other reports disagree. Maspin down-regulation in 
prostate cancer however, is less controversial. The differing results seen in clinical 
studies may be due to the lack of standardised methods. The sub-cellular localisation of 
maspin also needs further investigation, as well as the role of maspin in these 
compartments. The up-regulation of maspin in pancreatic and ovarian cancers seems to 
oppose its reported tumour suppressive function; however these cells may be non-
responsive to maspin, or may have high levels of mutation. The expression of mutant 
maspin may be an advantage to cancers of these tissues. 
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Expression of maspin is positively regulated by Ets, Apl, and p53 transcription factors. 
The binding sites for these factors and the negative HRE element are contained within 
500 bp of the transcription start site. Ets, Apl and p53 all play roles in cell proliferation 
and apoptosis. Ets and Apl also regulate cell differentiation. Androgen influences 
cellular differentiation and development. The development of tissues involves cellular 
migration, apoptosis, differentiation, and proliferation. The regulation of maspin by 
these factors suggests that maspin may be important for the development and 
differentiation of tissues. This hypothesis is supported by abnormal expression of 
maspin during pregnancy in W AP-maspin mice causing disrupted mammary gland 
development. These factors also support the functional evidence that maspin plays a 
role in apoptosis, as all activators of maspin transcription are involved in apoptosis 
regulation. Ets, Apl and AR play roles in cellular differentiation, and in prostate cancers 
the loss of maspin correlated with the loss of differentiation (higher tumour grade), 
however the role of maspin in cellular differentiation has not been studied. 
Repression of maspin transcription by methylation of the promoter may be important 
for tissue-specific regulation. This silencing mechanism may also be used by cells to 
silence maspin as cancer progresses. The methylation of the proximal CpG island in the 
maspin promoter results in histone deacetylation and chromatin compaction in this area. 
This then prevents transcription factors from activating transcription, causing the loss of 
the tumour suppressor functions of maspin, and thus allowing cancer progression. 
The mechanisms by which MnSOD, NO, and GLA stimulate maspin expression are yet 
to be deciphered, however NO may activate p53, and p53 in tum activate maspin 
expression. 
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1. 7 Research aims 
The elements that are involved in transcriptional regulation of maspin suggest that 
maspin is involved in apoptosis, cellular migration, and proliferation; hypotheses which 
are supported by functional studies. To date however, the molecular mechanisms of the 
function of maspin are unknown. The identification of further transcriptional elements 
which are involved in the transcriptional regulation of maspin may provide insights in 
the search for a molecular function of maspin. For example, if a transcriptional effector, 
responsible for activating transcription of genes which act in a particular apoptosis 
pathway, is identified as activating maspin transcription, then maspin may play a role in 
this pathway. This hypothesis can then be tested further. 
The regulatory elements that have been functionally identified to date are all contained 
within 500 bp of the transcriptional start site. Transient transfection of deletion series 
has shown that transcriptional elements may be present in regions further upstream from 
the TSS (Zhang et al., 1997a; Zhang et al., 1997b), however these regions have not been 
investigated. The reported activation of maspin expression by MnSOD, OLA, and NO 
also suggest that other transcriptional regulators may play a role in maspin expression. 
The aim of this study was to identify putative regulatory factors which are important for 
the regulation of the gene, by assessing the regulation of maspin transcription in 
cancerous and normal cell lines. To this end, the maspin gene was identified from the 
human genome sequence, and a fragment representing the promoter cloned and 
analysed for putative transcriptional elements. Transient transfection of cell lines with a 
series of maspin promoter deletion constructs was the first step in functional analysis. 
This was followed by footprinting of regions identified as being important for the 
regulation of the maspin gene. Footprinting has the potential to specifically identify 
protein binding motifs at the nucleotide level, enabling putative protein binding DNA 
elements to be identified. The DNA elements can then be used to predict the 
transcription factor which binds to this region. 
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